CPIG
TVTX icon

Chicago Partners Investment Group’s Travere Therapeutics TVTX Stock Holding History

Chicago Partners Investment Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,248
Closed -$152K – 599
2021
Q2 		$152K Buy
+11,248
New +$222K 0.01% 513

Other funds holding TVTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Chicago Partners Investment Group's TVTX Position: Q3 2021 in Review

Chicago Partners Investment Group sold out of Travere Therapeutics (TVTX) in Q3 2021, closing a stake of 11,248 shares — an estimated $152K sold.

Chicago Partners Investment Group first reported a position in TVTX in Q2 2021 and held it in 1 quarter. The position peaked at $152K in Q2 2021. 148 funds tracked by Wall St. Rank hold TVTX as of Q3 2021.

  • Chicago Partners Investment Group reported no remaining Travere Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Chicago Partners Investment Group sold 11,248 Travere Therapeutics shares in Q3 2021, an estimated $152K.
  • Chicago Partners Investment Group first reported a position in Travere Therapeutics in Q2 2021 and held it in 1 quarter.
  • Chicago Partners Investment Group's Travere Therapeutics position peaked at $152K in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2021.

Based on Chicago Partners Investment Group's 13F filing for Q3 2021, filed 12 Nov 2021.